KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Raw Materials: 2016-2025

Historic Raw Materials for Sarepta Therapeutics (SRPT) over the last 9 years, with Sep 2025 value amounting to $325.5 million.

  • Sarepta Therapeutics' Raw Materials rose 56.27% to $325.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $325.5 million, marking a year-over-year increase of 56.27%. This contributed to the annual value of $280.0 million for FY2024, which is 109.05% up from last year.
  • As of Q3 2025, Sarepta Therapeutics' Raw Materials stood at $325.5 million, which was up 3.39% from $314.9 million recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Raw Materials registered a high of $325.5 million during Q3 2025, and its lowest value of $59.2 million during Q4 2022.
  • For the 3-year period, Sarepta Therapeutics' Raw Materials averaged around $238.2 million, with its median value being $243.1 million (2023).
  • Per our database at Business Quant, Sarepta Therapeutics' Raw Materials plummeted by 74.29% in 2022 and then surged by 126.36% in 2023.
  • Over the past 5 years, Sarepta Therapeutics' Raw Materials (Quarterly) stood at $230.2 million in 2021, then tumbled by 74.29% to $59.2 million in 2022, then surged by 126.36% to $134.0 million in 2023, then soared by 109.05% to $280.0 million in 2024, then spiked by 56.27% to $325.5 million in 2025.
  • Its last three reported values are $325.5 million in Q3 2025, $314.9 million for Q2 2025, and $299.0 million during Q1 2025.